gms | German Medical Science

55. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)
1. Joint Meeting mit der Ungarischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

25. bis 28.04.2004, Köln

P53 pathway parameter expression in brain metastases

Expression der P53-Pathway-Parameter in Hirnmetastasen

Meeting Abstract

  • corresponding author Andreas M. Stark - Klinik für Neurochirurgie im Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel
  • H. Tscheslog - Klinik für Neurochirurgie im Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel
  • H. H. Hugo - Klinik für Neurochirurgie im Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel
  • H. M. Mehdorn - Klinik für Neurochirurgie im Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel
  • J. Held-Feindt - Klinik für Neurochirurgie im Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel

Deutsche Gesellschaft für Neurochirurgie. Ungarische Gesellschaft für Neurochirurgie. 55. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), 1. Joint Meeting mit der Ungarischen Gesellschaft für Neurochirurgie. Köln, 25.-28.04.2004. Düsseldorf, Köln: German Medical Science; 2004. DocP 04.42

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/dgnc2004/04dgnc0325.shtml

Published: April 23, 2004

© 2004 Stark et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Objective

Brain metastases are a major and increasingly common complication in cancer treatment. P53-dependent cell cycle control, though not fully understood, is a potential therapeutic target in cancer. The aim of this study was to estimate the expression of p53 pathway parameters p53, MDM2, p21, Bcl-2 and Bax in a large series of brain metastasis.

Methods

Paraffin-embedded tissue specimens from 139 patients were included who had undergone craniotomy for newly diagnosed brain metastases between 05/1994 and 10/2001 at our department. Tumor origin was non-small cell lung cancer (NSCLC; n=78), breast cancer (n=35), colorectal adenocarcinoma (n=17) and renal cancer (n=9). Immunohistochemical staining for p53, MDM2, p21, Bcl-2 and Bax was compared to corresponding primary tumors, to Ki67 proliferation index and patient survival.

Results

In comparison to primary tumors, Bax was significantly over expressed in brain metastases of all tumor types examined (p<0.001). Variable expression differences were noticed for other parameters: p53 expression was decreased in colorectal cancer brain lesions (p=0.048) and lost in renal cancer brain metastases. P21 was overexpressed in NSCLC (p=0.0001), colorectal (p=0.005) and renal cancer brain metastases. Bcl-2 was significantly decreased in breast and colorectal brain metastases (p<0.001) while there was a trend in NSCLC and renal cancer brain lesions. A high Ki67 was significantly associated with reduced survival (p=0.032) whereas there was no correlation between p53, MDM2, p21, Bcl-2 and Bax expression versus survival.

Conclusions

Pro-apoptotic Bax and G1-cell cycle inhibitor p21 were significantly overexpressed in brain metastases of different origin when compared to corresponding primary tumors. In contrast, p53 and anti-apoptotic Bcl-2 expression was decreased. A high Ki67 PI indicated reduced survival while there was no correlation between p53 parameter expression and patient survival.